These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 21232036)

  • 1. Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease.
    Van Broeck B; Chen JM; Tréton G; Desmidt M; Hopf C; Ramsden N; Karran E; Mercken M; Rowley A
    Br J Pharmacol; 2011 May; 163(2):375-89. PubMed ID: 21232036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.
    Rogers K; Felsenstein KM; Hrdlicka L; Tu Z; Albayya F; Lee W; Hopp S; Miller MJ; Spaulding D; Yang Z; Hodgdon H; Nolan S; Wen M; Costa D; Blain JF; Freeman E; De Strooper B; Vulsteke V; Scrocchi L; Zetterberg H; Portelius E; Hutter-Paier B; Havas D; Ahlijanian M; Flood D; Leventhal L; Shapiro G; Patzke H; Chesworth R; Koenig G
    Mol Neurodegener; 2012 Dec; 7():61. PubMed ID: 23249765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization of the novel γ-secretase modulator AS2715348, a potential therapy for Alzheimer's disease, in rodents and nonhuman primates.
    Mitani Y; Akashiba H; Saita K; Yarimizu J; Uchino H; Okabe M; Asai M; Yamasaki S; Nozawa T; Ishikawa N; Shitaka Y; Ni K; Matsuoka N
    Neuropharmacology; 2014 Apr; 79():412-9. PubMed ID: 24373902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological properties of a novel and potent γ-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease.
    Murakami K; Watanabe T; Koike T; Kamata M; Igari T; Kondo S
    Brain Res; 2016 Feb; 1633():73-86. PubMed ID: 26707977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of glutaminyl cyclase ameliorates amyloid pathology in an animal model of Alzheimer's disease via the modulation of γ-secretase activity.
    Song H; Chang YJ; Moon M; Park SK; Tran PT; Hoang VH; Lee J; Mook-Jung I
    J Alzheimers Dis; 2015; 43(3):797-807. PubMed ID: 25114069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain.
    Bürger S; Noack M; Kirazov LP; Kirazov EP; Naydenov CL; Kouznetsova E; Yafai Y; Schliebs R
    Int J Dev Neurosci; 2009 Oct; 27(6):517-23. PubMed ID: 19589380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
    Imbimbo BP; Hutter-Paier B; Villetti G; Facchinetti F; Cenacchi V; Volta R; Lanzillotta A; Pizzi M; Windisch M
    Br J Pharmacol; 2009 Mar; 156(6):982-93. PubMed ID: 19239474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calsyntenin-3 C-terminal fragment accumulates in dystrophic neurites surrounding aβ plaques in tg2576 mouse and Alzheimer disease brains: its neurotoxic role in mediating dystrophic neurite formation.
    Uchida Y; Gomi F; Murayama S; Takahashi H
    Am J Pathol; 2013 May; 182(5):1718-26. PubMed ID: 23499467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment.
    Brendel M; Jaworska A; Herms J; Trambauer J; Rötzer C; Gildehaus FJ; Carlsen J; Cumming P; Bylund J; Luebbers T; Bartenstein P; Steiner H; Haass C; Baumann K; Rominger A
    Mol Psychiatry; 2015 Oct; 20(10):1179-87. PubMed ID: 26055427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological and Toxicological Properties of the Potent Oral
    Wagner SL; Rynearson KD; Duddy SK; Zhang C; Nguyen PD; Becker A; Vo U; Masliah D; Monte L; Klee JB; Echmalian CM; Xia W; Quinti L; Johnson G; Lin JH; Kim DY; Mobley WC; Rissman RA; Tanzi RE
    J Pharmacol Exp Ther; 2017 Jul; 362(1):31-44. PubMed ID: 28416568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
    Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
    Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.
    Best JD; Smith DW; Reilly MA; O'Donnell R; Lewis HD; Ellis S; Wilkie N; Rosahl TW; Laroque PA; Boussiquet-Leroux C; Churcher I; Atack JR; Harrison T; Shearman MS
    J Pharmacol Exp Ther; 2007 Feb; 320(2):552-8. PubMed ID: 17099072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
    Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
    FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
    Sivilia S; Lorenzini L; Giuliani A; Gusciglio M; Fernandez M; Baldassarro VA; Mangano C; Ferraro L; Pietrini V; Baroc MF; Viscomi AR; Ottonello S; Villetti G; Imbimbo BP; Calzà L; Giardino L
    BMC Neurosci; 2013 Apr; 14():44. PubMed ID: 23560952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral treatment with enoxaparin exacerbates amyloid plaque pathology in Tg2576 mice.
    Cui H; King AE; Jacobson GA; Small DH
    J Neurosci Res; 2017 Apr; 95(4):992-999. PubMed ID: 27546887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.
    Kawarabayashi T; Younkin LH; Saido TC; Shoji M; Ashe KH; Younkin SG
    J Neurosci; 2001 Jan; 21(2):372-81. PubMed ID: 11160418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
    Kukar T; Prescott S; Eriksen JL; Holloway V; Murphy MP; Koo EH; Golde TE; Nicolle MM
    BMC Neurosci; 2007 Jul; 8():54. PubMed ID: 17650315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.